同型半胱氨酸在绝经后女性心血管疾病中的研究进展

doi:10.12280/gjfckx.20210115

摘要/Abstract

摘要：

绝经意味着女性卵巢功能衰竭,性激素水平改变导致女性出现一系列绝经相关症状,近期可出现血管舒缩症状如潮热、盗汗,神经精神症状等,远期危害可出现心血管疾病（cardiovascular disease,CVD）、骨质疏松、糖脂代谢紊乱、泌尿生殖道萎缩等全身各器官系统退行性病变。绝经后女性CVD发病风险升高,是中老年女性致死、致残的重要原因。同型半胱氨酸（homocysteine,Hcy）是一种含巯基的氨基酸,是甲硫氨酸循环的中间代谢产物,与CVD的发生发展密切相关,被认为是CVD的独立危险因素。近年来相关研究表明绝经后女性Hcy水平及高同型半胱氨酸血症（hyperhomocysteinemia,HHcy）发生率均高于绝经前女性。绝经后升高的Hcy水平与CVD发生风险具有关联,Hcy可能在绝经后CVD中发挥重要作用。人体内Hcy水平可能受雌激素等性激素调控,绝经激素治疗（menopause hormone therapy,MHT）可降低女性Hcy水平,对降低绝经后CVD的发生风险有积极作用。

关键词: 同型半胱氨酸, 绝经期, 高同型半胱氨酸血症, 心血管疾病, 性腺甾类激素, 绝经激素治疗

Abstract:

Menopause means ovarian failure and changes in sex hormone levels, which lead to a series of menopause-related symptoms, including short-term vasomotor symptoms such as hot flashes, night sweats, neuropsychiatric symptoms, etc. Menopause also results in degenerative diseases in main organs and systems including cardiovascular diseases (CVD), osteoporosis, disorders of glucose and lipid metabolism, and urogenital atrophy. Postmenopausal women have an increased risk of CVD,which is the leading cause of mortality and an important cause of disability in middle-aged and old women. Homocysteine is a sulfhydryl-containing amino acid and an intermediate metabolite of the methionine cycle. It is closely related to the occurrence and development of CVD and is considered as an independent risk factor of CVD. In recent years, studies have shown that Hcy levels and the incidence of hyperhomocysteinemia (HHcy) are higher in postmenopausal women than in premenopausal women. The elevated Hcy level after menopause is associated with higher risks of CVD, and Hcy may play an important role in postmenopausal CVD. Serum Hcy levels may be regulated by sex hormones such as estrogen. Menopausal hormone therapy (MHT) can reduce Hcy levels in women and may have a positive effect on decreasing the risks of postmenopausal CVD.

Key words: Homocysteine, Menopause, Hyperhomocysteinemia, Cardiovascular diseases, Gonadal steroid hormones, Menopause hormone therapy

王园园, 黄艺舟, 许凌. 同型半胱氨酸在绝经后女性心血管疾病中的研究进展[J]. 国际妇产科学杂志, 2021, 48(4): 429-433.

WANG Yuan-yuan, HUANG Yi-zhou, XU Ling. Research Progress of Homocysteine in Cardiovascular Diseases in Postmenopausal Women[J]. Journal of International Obstetrics and Gynecology, 2021, 48(4): 429-433.

参考文献 31

[1]	El Khoudary SR. Age at menopause onset and risk of cardiovascular disease around the world[J]. Maturitas, 2020, 141:33-38. doi: 10.1016/j.maturitas.2020.06.007. doi: 10.1016/j.maturitas.2020.06.007
[2]	Esse R, Barroso M, Tavares de Almeida I, et al. The Contribution of Homocysteine Metabolism Disruption to Endothelial Dysfunction: State-of-the-Art[J]. Int J Mol Sci, 2019, 20(4):867. doi: 10.3390/ijms20040867. doi: 10.3390/ijms20040867
[3]	Zaric BL, Obradovic M, Bajic V, et al. Homocysteine and Hyperhomocysteinaemia[J]. Curr Med Chem, 2019, 26(16):2948-2961. doi: 10.2174/0929867325666180313105949. doi: 10.2174/0929867325666180313105949
[4]	中国高血压防治指南修订委员会, 高血压联盟, 中华医学会心血管病学分会中国医师协会高血压专业委员会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1):24-56. doi: 10.3969/j.issn.1007-5410.2019.01.002. doi: 10.3969/j.issn.1007-5410.2019.01.002
[5]	McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis[J]. Am J Pathol, 1969, 56(1):111-128. pmid: 5792556
[6]	Djuric D, Jakovljevic V, Zivkovic V, et al. Homocysteine and homocysteine-related compounds: an overview of the roles in the pathology of the cardiovascular and nervous systems[J]. Can J Physiol Pharmacol, 2018, 96(10):991-1003. doi: 10.1139/cjpp-2018-0112. doi: 10.1139/cjpp-2018-0112
[7]	Zhang Z, Gu X, Fang X, et al. Homocysteine and the Risk of Cardiovascular Events and All-Cause Death in Elderly Population: A Community-Based Prospective Cohort Study[J]. Ther Clin Risk Manag, 2020, 16:471-481. doi: 10.2147/TCRM.S239496. doi: 10.2147/TCRM.S239496
[8]	Feng Y, Kang K, Xue Q, et al. Value of plasma homocysteine to predict stroke, cardiovascular diseases, and new-onset hypertension: A retrospective cohort study[J]. Medicine(Baltimore), 2020, 99(34):e21541. doi: 10.1097/MD.0000000000021541. doi: 10.1097/MD.0000000000021541
[9]	Hak AE, Polderman KH, Westendorp IC, et al. Increased plasma homocysteine after menopause[J]. Atherosclerosis, 2000, 149(1):163-168. doi: 10.1016/s0021-9150(99)00321-4. doi: 10.1016/s0021-9150(99)00321-4 pmid: 10704628
[10]	Zhu Z, Jiang S, Li C, et al. Relationship between serum homocysteine and different menopausal stage[J]. Climacteric, 2020, 23(1):59-64. doi: 10.1080/13697137.2019.1634045. doi: 10.1080/13697137.2019.1634045 pmid: 31294633
[11]	Wang Y, Jiang Y, Wang N, et al. Central But Not General Obesity Is Positively Associated with the Risk of Hyperhomocysteinemia in Middle-Aged Women[J]. Nutrients, 2019, 11(7):1614. doi: 10.3390/nu11071614. doi: 10.3390/nu11071614
[12]	陈瑛. 年龄、绝经状态与同型半胱氨酸水平的关系[J]. 国际妇产科学杂志, 2015, 42(2):191-193.
[13]	Ridker PM, Manson JE, Buring JE, et al. Homocysteine and risk of cardiovascular disease among postmenopausal women[J]. JAMA, 1999, 281(19):1817-1821. doi: 10.1001/jama.281.19.1817. doi: 10.1001/jama.281.19.1817
[14]	朱小莉, 刘芳, 王晓峰. 同型半胱氨酸及雌激素对老年女性冠状动脉病变的影响[J]. 中国老年学杂志, 2015, 35(21):6083-6085. doi: 10.3969/j.issn.1005-9202.2015.21.035. doi: 10.3969/j.issn.1005-9202.2015.21.035
[15]	Keller AC, Klawitter J, Hildreth KL, et al. Elevated plasma homocysteine and cysteine are associated with endothelial dysfunction across menopausal stages in healthy women[J]. J Appl Physiol(1985), 2019, 126(6):1533-1540. doi: 10.1152/japplphysiol.00819.2018. doi: 10.1152/japplphysiol.00819.2018
[16]	Bourgonje AR, Abdulle AE, Al-Rawas AM, et al. Systemic Oxidative Stress Is Increased in Postmenopausal Women and Independently Associates with Homocysteine Levels[J]. Int J Mol Sci, 2020, 21(1):314. doi: 10.3390/ijms21010314. doi: 10.3390/ijms21010314
[17]	Al Mutairi F. Hyperhomocysteinemia: Clinical Insights[J]. J Cent Nerv Syst Dis, 2020, 12:1179573520962230. doi: 10.1177/1179573520962230. doi: 10.1177/1179573520962230
[18]	Cohen E, Margalit I, Shochat T, et al. Gender differences in homocysteine concentrations, a population-based cross-sectional study[J]. Nutr Metab Cardiovasc Dis, 2019, 29(1):9-14. doi: 10.1016/j.numecd.2018.09.003. doi: S0939-4753(18)30273-4 pmid: 30459075
[19]	Xu R, Huang F, Wang Y, et al. Gender- and age-related differences in homocysteine concentration: a cross-sectional study of the general population of China[J]. Sci Rep, 2020, 10(1):17401. doi: 10.1038/s41598-020-74596-7. doi: 10.1038/s41598-020-74596-7
[20]	Michels KA, Wactawski-Wende J, Mills JL, et al. Folate, homocysteine and the ovarian cycle among healthy regularly menstruating women[J]. Hum Reprod, 2017, 32(8):1743-1750. doi: 10.1093/humrep/dex233. doi: 10.1093/humrep/dex233
[21]	Zhang D, Hong X, Wang J, et al. Estradiol-17β inhibits homocysteine mediated damage by promoting H(2) S production via upregulating CBS and CSE expression in human umbilical vein endothelial cells[J]. J Cell Biochem, 2019 Nov 14. doi: 10.1002/jcb.29527. doi: 10.1002/jcb.29527
[22]	Chang H, Xie L, Ge H, et al. Effects of hyperhomocysteinaemia and metabolic syndrome on reproduction in women with polycystic ovary syndrome: a secondary analysis[J]. Reprod Biomed Online, 2019, 38(6):990-998. doi: 10.1016/j.rbmo.2018.12.046. doi: S1472-6483(19)30024-0 pmid: 30979610
[23]	Nakhai Pour HR, Grobbee DE, Muller M, et al. Serum sex hormone and plasma homocysteine levels in middle-aged and elderly men[J]. Eur J Endocrinol, 2006, 155(6):887-893. doi: 10.1530/eje.1.02303. doi: 10.1530/eje.1.02303 pmid: 17132759
[24]	乔林, 熊英, 徐克惠. “中国绝经管理和绝经激素治疗指南(2018)”解读[J]. 实用妇产科杂志, 2019, 35(3):184-187.
[25]	Whitmer RA, Haan MN, Miller JW, et al. Hormone replacement therapy and cognitive performance: the role of homocysteine[J]. J Gerontol A Biol Sci Med Sci, 2003, 58(4):324-330. doi: 10.1093/gerona/58.4.m324. doi: 10.1093/gerona/58.4.m324
[26]	Lakryc EM, Machado RB, Soares JM Jr, et al. What is the influence of hormone therapy on homocysteine and crp levels in postmenopausal women?[J]. Clinics(Sao Paulo), 2015, 70(2):107-113. doi: 10.6061/clinics/2015(02)07. doi: 10.6061/clinics/2015(02)07
[27]	Williams MS, Cushman M, Ouyang P, et al. Association of Serum Sex Hormones with Hemostatic Factors in Women On and Off Hormone Therapy: The Multiethnic Study of Atherosclerosis[J]. J Womens Health(Larchmt), 2016, 25(2):166-172. doi: 10.1089/jwh.2015.5465. doi: 10.1089/jwh.2015.5465
[28]	胡平, 王蔼明, 宋志琴, 等. 雌二醇屈螺酮片对绝经后女性血清中同型半胱氨酸的影响[J]. 生殖医学杂志, 2015, 24(7):559-562. doi: 10.3969/j.issn.1004-3845.2015.07.010. doi: 10.3969/j.issn.1004-3845.2015.07.010
[29]	裴文静. 绝经后健康妇女激素补充治疗与血浆同型半胱氨酸关系的Meta分析[D]. 南昌:南昌大学, 2020.
[30]	Gökkuşu C, Özbek Z, Tata G. Hormone replacement therapy: relation to homocysteine and prooxidant-antioxidant status in healthy postmenopausal women[J]. Arch Gynecol Obstet, 2012, 285(3):733-739. doi: 10.1007/s00404-011-2051-2. doi: 10.1007/s00404-011-2051-2 pmid: 21877144
[31]	Taşçı T, Şükür YE, Özmen B, et al. Effects of transdermal and oral hormone replacement therapies on monocyte chemoattractant protein-1 levels: a randomized clinical trial[J]. Eur J Obstet Gynecol Reprod Biol, 2014, 176:50-54. doi: 10.1016/j.ejogrb.2014.02.034. doi: 10.1016/j.ejogrb.2014.02.034